- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Phase 2 Data results promising: Monoclonal Antibody Lu AG09222 Reduces Migraine Days Significantly Over Placebo
![Phase 2 Data results promising: Monoclonal Antibody Lu AG09222 Reduces Migraine Days Significantly Over Placebo Phase 2 Data results promising: Monoclonal Antibody Lu AG09222 Reduces Migraine Days Significantly Over Placebo](https://medicaldialogues.in/h-upload/2023/10/20/750x450_223365-migraine.webp)
Denmark: A recent Phase 2 clinical trial (HOPE trial) has yielded promising results for a new treatment aimed at preventing migraines. The trial evaluated Lu AG09222, a humanized monoclonal antibody targeting pituitary adenylate cyclase-activating polypeptide (PACAP), and found that a single intravenous infusion of 750 mg significantly reduced the frequency of migraines compared to a placebo.
"A single intravenous infusion of 750 mg of Lu AG09222 demonstrated a significant reduction in migraine frequency compared to placebo over the following four weeks," the researchers wrote in the New England Journal of Medicine.
Migraine sufferers often face debilitating symptoms, including intense headaches, nausea, and sensitivity to light and sound. Current treatments offer varying degrees of relief, but many patients continue to experience frequent and severe attacks. The introduction of new preventive therapies is, therefore, a crucial area of research.
Targeting pituitary adenylate cyclase-activating polypeptide represents a novel approach to migraine treatment. Therefore, Messoud Ashina, University of Copenhagen (M.A.), Copenhagen, Denmark, and colleagues aimed to determine the safety and efficacy of intravenous Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, for migraine prevention.
For this purpose, the researchers conducted a Phase 2, double-blind, randomized, placebo-controlled trial involving adult participants aged 18 to 65 who had experienced insufficient benefit from two to four prior preventive migraine treatments. The trial featured a 4-week treatment period followed by an 8-week follow-up.
Participants were randomly assigned in a 2:1:2 ratio to receive either a single intravenous infusion of 750 mg of Lu AG09222, 100 mg of Lu AG09222, or a placebo. The primary endpoint was the mean change from baseline in the number of migraine days per month during the first four weeks, specifically comparing the 750-mg Lu AG09222 group with the placebo group.
The researchers reported the following findings:
- Of 237 participants enrolled, 97 received 750 mg of Lu AG09222, 46 received 100 mg of Lu AG09222, and 94 received placebo.
- The mean number of baseline migraine days per month was 16.7 in the overall population, and the mean change from baseline over weeks 1 through 4 was −6.2 days in the Lu AG09222 750-mg group, compared with −4.2 days in the placebo group.
- Adverse events with a higher incidence in the Lu AG09222 750-mg group than in the placebo group during the 12-week observation period included coronavirus disease 2019 (7% versus 3%), nasopharyngitis (7% versus 4%), and fatigue (5% versus 1%).
"If successful, Lu AG09222 could represent a significant advancement in migraine therapy, offering hope for those seeking more effective solutions to manage their condition," the researchers concluded.
Reference:
DOI: 10.1056/NEJMoa2314577
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751